2. Search Result
Search Result
Results for "

MEFs

" in MedChemExpress (MCE) Product Catalog:

75

Inhibitors & Agonists

6

Fluorescent Dye

2

Biochemical Assay Reagents

4

Peptides

4

Natural
Products

1

Isotope-Labeled Compounds

13

Oligonucleotides

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0988
    Deferoxamine mesylate
    Maximum Cited Publications
    397 Publications Verification

    Desferrioxamine B mesylate; DFOM

    		 Autophagy HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine mesylate
  • HY-B1625
    Deferoxamine
    Maximum Cited Publications
    397 Publications Verification

    Deferoxamine B; Deferriferrioxamine B; Deferrioxamine

    		 HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Autophagy Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine
  • HY-W187305
    MASM7
    5 Publications Verification

    		 Mitochondrial Metabolism Others
    MASM7 is a mitofusin activator, and can achieve mitochondrial fusion via mitofusins. MASM7 can increase Mito AR with an EC50 value of 75 nM in MEFs in concentration-responsively, and can promote mitochondrial fusion by directly activating MFN2 or MFN. MASM7 also demonstrates direct binding to the HR2 domain of MFN2 with Kd value of 1.1 μM .
    MASM7
  • HY-124817
    Col003
    5+ Cited Publications

    		 HSP Inflammation/Immunology
    Col003 is a selective and potent inhibitor of Hsp47 and competitively binds to the collagen binding site on Hsp47 (IC50=1.8 μM). Col003 discourages the interaction of Hsp47 with collagen and inhibits collagen secretion by destabilizing the collagen triple helix. Col003 can be used for the investigation of fibrosis
    Col003
  • HY-136386
    N-Acetyl-D-cysteine
    3 Publications Verification

    		 Reactive Oxygen Species (ROS) Others
    N-Acetyl-D-cysteine has antioxidant activities and scavenges ROS through the reaction with its thiol group, but cannot enter the glutathione metabolic pathway .
    N-Acetyl-D-cysteine
  • HY-33878
    2-PPA

    		Potassium Channel Proton Pump Neurological Disease
    2-PPA is a lysosomal potassium and proton channel TMEM175 pore blocker. 2-PPA binds at a TMEM175 pore site to occlude potassium and proton ion permeation pathways. 2-PPA increases lysosomal macromolecule catabolism, accelerates macropinocytosis. 2-PPA binds to hepatic protein in covalent. 2-PPA can be used for the research of Parkinson's disease .
    2-PPA
  • HY-115576
    P62-mediated mitophagy inducer
    5 Publications Verification

    		 p62 Mitophagy Autophagy Mitosis Neurological Disease Cancer
    P62-mediated mitophagy inducer (PMI) is a P62-mediated mitophagy activator. P62-mediated mitophagy inducer activates mitochondrial autophagy without recruitment of Parkin or collapse of the mitochondrial membrane potential and remains active in cells lacking a fully functional PINK1/Parkin pathway. P62-mediated mitophagy inducer serves as a pharmacological tool to study the molecular mechanisms of mitosis, avoiding toxicity and some of the non-specific effects associated with the sudden dissipation of mitochondria lacking membrane potential .
    P62-mediated mitophagy inducer
  • HY-P1680
    Astin C

    Asterin

    		 STING HSV Infection Inflammation/Immunology Cancer
    Astin C (Asterin) is a cyclopeptide that can be extracted from Aster tataricus. Astin C has anti-inflammatory and anti-cancer activities. Astin C can specifically inhibit the cGAS-STING signaling pathway, block the recruitment of IRF3 to the STING signalosome, and thus inhibit the innate inflammatory response. Astin C can be used in the research of autoimmune diseases and cancers .
    Astin C
  • HY-125402
    GSK-843
    5+ Cited Publications

    GSK'843

    		 RIP kinase Apoptosis Inflammation/Immunology
    GSK-843 (GSK'843) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 8.6 nM, and inhibits kinase activity with an IC50 of 6.5 nM. GSK-843 can be used for the research of inflammation .
    GSK-843
  • HY-30216A
    Leucic acid

    α-Hydroxyisocaproic acid

    		 Drug Metabolite Hydroxycarboxylic Acid Receptor (HCAR) AMPK ERK Metabolic Disease Inflammation/Immunology
    Leucic acid (α-Hydroxyisocaproic acid) is an orally active end-product of the microbial metabolism of leucine. Leucic acid can bind to HCAR2, alters AMPK and ERK1/2 phosphorylation status, suppresses lipid synthesis, promotes catabolism, reduces adiposity, enhances lean mass and exercise capacity. Leucic acid suppresses pro-inflammatory cytokine secretion, inflammation-related gene mRNA expression. Leucic acid decreases basal protein synthesis, attenuates myotube atrophy. Leucic acid can be used for the research of obesity .
    Leucic acid
  • HY-172262
    WEHI-3773

    		VDAC Bcl-2 Family Apoptosis Cancer
    WEHI-3773 is a VDAC2 ligand and apoptosis modulator. WEHI-3773 directly binds to the β7-β10 region of VDAC2 and disrupts its interaction with BAX and BAK. WEHI-3773 regulates BAX-mediated apoptosis in BAK-deficient cells by modulating conformational activation of BAX, mitochondrial redistribution, and cytochrome c release. WEHI-3773 overcomes Venetoclax (HY-15531) resistance, resensitizes leukemia cells carrying BAX mutations to BH3 mimetics, and enables long-term clonogenic survival of BAK-deficient cells treated with BH3 mimetics. WEHI-3773 is applicable to research related to acute myeloid leukemia .
    WEHI-3773
  • HY-19350
    BML-210
    2 Publications Verification

    		 HDAC Apoptosis Cancer
    BML-210 is a potent HDAC inhibitor. BML-210 can inhibit the HDAC4-VP16-driven reporter signal with an apparent IC50 of ∼5 µM. BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction. BML-210 causes an increase in the G0/G1 phase. BML-210 induces apoptosis and displays antitumour activities in orthotopic mammary tumours in mice .
    BML-210
  • HY-120877
    MRT199665

    		MARK Salt-inducible Kinase (SIK) AMPK Apoptosis Cancer
    MRT199665 is a potent and ATP-competitive, selective MARK/SIK/AMPK inhibitor with IC50s of 2/2/3/2 nM, 10/10 nM, and 110/12/43 nM for MARK1/MARK2/MARK3/MARK14, AMPKα1/AMPKα2, and SIK1/SIK2/SIK3, respectively . MRT199665 causes apoptosis in MEF2C-activated human acute myeloid leukemias (AML) cells . MRT199665 inhibits the phosphorylation of SIK substrate CRTC3 at S370 .
    MRT199665
  • HY-128341
    ERK5-IN-2

    		ERK Cardiovascular Disease Cancer
    ERK5-IN-2 is an orally active, sub-micromolar, selective ERK5 inhibitor with IC50s of 0.82 μM, 3 μM for ERK5 and ERK5 MEF2D, respectively. ERK5-IN-2 does not interact with the BRD4 bromodomain. ERK5-IN-2 suppresses both tumor xenograft growth and basic fibroblast growth factor (bFGF) driven Matrigel plug angiogenesis .
    ERK5-IN-2
  • HY-W123005
    Dimethyl pimelimidate dihydrochloride
    1 Publications Verification

    		 Biochemical Assay Reagents Others
    Dimethyl pimelimidate dihydrochloride is a bifunctional imidoester protein-protein crosslinker used in chromatin immunoprecipitation (ChIP) assays .
    Dimethyl pimelimidate dihydrochloride
  • HY-P2726
    Aldolase, Rabbit muscle

    Fructose-diphosphate aldolase

    		 Fructose-1,6-bisphosphate aldolase Endogenous Metabolite Metabolic Disease
    Aldolase, Rabbit muscle (Fructose-diphosphate aldolase) is a glycolytic enzyme and glucose availability sensor. Aldolase, Rabbit muscle catalyzes the reversible carbon-carbon cleavage of fructose-1,6-bisphosphate to produce dihydroxyacetone phosphate and glyceraldehyde 3-phosphate. Aldolase, Rabbit muscle is an essential component for v-ATPase activity. Aldolase, Rabbit muscle participates in processes such as gluconeogenesis, the Calvin cycle and glycolysis .
    Aldolase, Rabbit muscle
  • HY-B0988R
    Deferoxamine mesylate (Standard)

    Desferrioxamine B mesylate (Standard); DFOM (Standard)

    		 Reference Standards Autophagy HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine (mesylate) (Standard) is the analytical standard of Deferoxamine (mesylate). This product is intended for research and analytical applications. Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine mesylate (Standard)
  • HY-D1422
    ER Tracker Yellow

    BDNCA-346

    		 Fluorescent Dye Others
    ER Tracker Yellow is an endoplasmic reticulum-targeted temperature-visible fluorescent probe. ER Tracker Yellow has high temperature sensitivity (3.9%/°C) and is not affected by pH and Ca 2+ interference. ER Tracker Yellow can be used for real-time monitoring of local temperature changes in the ER area. ER Tracker Yellow maintains its function in fixed cells. ER Tracker Yellow is suitable for various cell lines and primary cells, such as HeLa cells, MEF cells, and other cells .
    ER Tracker Yellow
  • HY-141591
    CYT296

    		Biochemical Assay Reagents Others
    CYT296 is a target chromatin de-condensation compound. CYT296 can improve the induction of induced pluripotent stem cell (iPSCs) mediated by defined factors (OSKM) and induce an open chromatin state in Mouse Embryonic Fibroblast (MEFs) to facilitate somatic cell reprogramming. CYT296 can be used for cell replacement therapies and drug screening research .
    CYT296
  • HY-115701
    1-Stearoyl-2-15(S)-Hpete-Sn-Glycero-3-Pe

    1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-phosphoethanolamine; 15(S)-HpETE-SAPE; 15(S)-hydroperoxyeicostetraenoic acid-SAPE

    		 Ferroptosis Inflammation/Immunology
    1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-Pe is a phospholipid that contains stearic acid (HY-B2219) at the sn-1 position and 15(S)-HpETE at the sn-2 position. It is produced via oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-Pe (SAPE) by 15-lipoxygenase (15-LO). 1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-Pe (0.6 and 0.9 μM) increases ferroptotic cell death in wild-type and Acsl4 knockout Pfa1 mouse embryonic fibroblasts (MEFs) treated with the GPX4 inhibitor RSL3.
    1-Stearoyl-2-15(S)-Hpete-Sn-Glycero-3-Pe
  • HY-164288
    TDI-6570

    TDI-006570

    		 Cyclic GMP-AMP Synthase STING Neurological Disease Inflammation/Immunology
    TDI-6570 (TDI-006570) is a blood-brain barrier-permeable, orally active cGAS inhibitor with an IC50 of 1.64 μM. TDI-6570 exhibits high gastrointestinal absorption and a long brain half-life in mice, and shows no toxicity to primary neurons. By inhibiting the cGAS-STING-IFN signaling pathway, TDI-6570 reduces STING levels and the activation of TBK1, blocks double-stranded DNA-induced cGAS activation and downstream interferon-stimulated gene expression, thereby reducing tau protein spread and improving synaptic loss. TDI-6570 reverses memory deficits, increases the amplitude of long-term potentiation, enhances the MEF2C transcriptional network, restores PSD-95 and vGAT punctate structures, and significantly improves cognitive resilience. TDI-6570 can be applied to the research of Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, as well as various central nervous system and autoimmune diseases .
    TDI-6570
  • HY-W177546
    CD00509

    		Phosphodiesterase (PDE) Apoptosis Caspase DNA/RNA Synthesis Cancer
    CD00509 is a tyrosyl-DNA phosphodiesterase (PDE) Tdp1 inhibitor with an IC50 of 0.71 μM. CD00509 increases DNA damage and promotes apoptosis of MCF-7 cells. CD00509 can sensitize breast cancer cells and wild-type murine embryonic fibroblasts (MEFs) to Camptothecin (CPT) (HY-16560). CD00509 can be used for the study of cancers such as breast cancer .
    CD00509
  • HY-P3513
    β-Neo-Endorphin

    		ERK MMP Neurological Disease
    β-Neo-Endorphin is an endogenous opioid peptide. β-Neo-Endorphin is a hypothalamic “big” Leu-enkephalin of porcine origin. β-Neo-Endorphin shows activation of the Erk1/2, MMP-2 and MMP-9 .
    β-Neo-Endorphin
  • HY-117987
    CPS-11

    N-(Hydroxymethyl)thalidomide

    		 Nuclear Factor of activated T Cells (NFAT) NF-κB Reactive Oxygen Species (ROS) Cancer
    CPS-11 (N-(Hydroxymethyl)thalidomide) a Thalidomide (HY-14658) analogue, is a potent anti-cancer agent. CPS-11 inhibits NF-κB, activates NFAT, and repress cytokine expression through elevated ROS. CPS-11 exhibits a wider activity spectrum and higher potency against MM (multiple myeloma) cell lines .
    CPS-11
  • HY-147284
    PI3K-IN-37

    		PI3K mTOR Others
    PI3K-IN-37 (Example 84.1) is a PI3K α/β/δ inhibitor with IC50s of 6, 8, 4 nM, respectively. PI3K-IN-37 can also inhibit mTOR (IC50=4 nM) .
    PI3K-IN-37
  • HY-128034
    PPIase-Parvulin inhibitor

    		PIN1 Cancer
    PPIase-Parvulin inhibitor (compound B) is a cell-permeable inhibitor targeting PPIase Pin1 and Par14, with IC50s of 1.5 and 1.0 µM, respectively. PPIase-Parvulin inhibitor has anticancer activity and inhibits the growth and proliferation of mouse embryonic fibroblasts (MEFs) .
    PPIase-Parvulin inhibitor
  • HY-120904
    AMPK-IN-1

    		AMPK Metabolic Disease
    AMPK-IN-1 is an activator of AMPK (EC50: 551 nM for isoform α2β2γ1). AMPK-IN-1 leads to eEF2 phosphorylation in a mTORC1-independent way .
    AMPK-IN-1
  • HY-153413
    Kras4B G12D-IN-1

    		Ras Cancer
    Kras4B G12D-IN-1 is a Kras4B G12D inhibitor with anticancer effects. Kras4B G12D-IN-1 decreases Kras protein expression in mouse embryonic fibroblasts (MEF) expressing Kras4B G12D (WO2016179558A1, Comp 994566) .
    Kras4B G12D-IN-1
  • HY-B1625R
    Deferoxamine (Standard)
    3 Publications Verification

    Deferoxamine B (Standard); Deferriferrioxamine B (Standard); Deferrioxamine (Standard)

    		 Reference Standards HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Autophagy Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine (Standard) is the analytical standard of Deferoxamine. This product is intended for research and analytical applications. Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine (Standard)
  • HY-W039939
    2-Azido-2-deoxy-D-glucose, 98%

    2-ADG, 98%

    		 Biochemical Assay Reagents OGT Cancer
    2-Azido-2-deoxy-D-glucose, 98% (2-ADG, 98%) is a substrate of O-GlcNAc transferase (OGT). 2-Azido-2-deoxy-D-glucose, 98% can be transferred from UDP-GlcAz to proteins in vitro via OGT mediation. When delivered as AcGlcAz, 2-Azido-2-deoxy-D-glucose, 98% enables the labeling and investigation of O-GlcNAc-modified nuclear and cytoplasmic proteins in cells. 2-Azido-2-deoxy-D-glucose, 98% undergoes strain-promoted [3+2] azide-alkyne cycloaddition (SPAAC) with technetium- 99m-labeled dibenzocyclooctyne derivatives in vivo. 2-Azido-2-deoxy-D-glucose, 98% can be used in sarcoma-related research .
    2-Azido-2-deoxy-D-glucose, 98%
  • HY-110067
    VO-OHPic

    		PTEN Apoptosis Autophagy Ferroptosis Reactive Oxygen Species (ROS) Interleukin Related Akt Keap1-Nrf2 Cardiovascular Disease Inflammation/Immunology Cancer
    VO-OHPic is a reversible, noncompetitive PTEN inhibitor with an human IC50 value of 46 nM. VO-OHPic inhibits PTEN signaling, activates Akt-GSK3β and Nrf-2/HO-1 pathways, induces apoptosis resistance and elevates IL-10 levels. VO-OHPic inhibits autophagy, ferroptosis and oxidative stress. VO-OHPic can be used for the research of acute myocardial infarction, intervertebral disc degeneration, cardiomyopathy and cancer .
    VO-OHPic
  • HY-RS08309
    MEF2A Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MEF2A Human Pre-designed siRNA Set A contains three designed siRNAs for MEF2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MEF2A Human Pre-designed siRNA Set A
    MEF2A Human Pre-designed siRNA Set A
  • HY-RS08312
    MEF2D Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MEF2D Human Pre-designed siRNA Set A contains three designed siRNAs for MEF2D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MEF2D Human Pre-designed siRNA Set A
    MEF2D Human Pre-designed siRNA Set A
  • HY-RS08311
    MEF2C Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MEF2C Human Pre-designed siRNA Set A contains three designed siRNAs for MEF2C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MEF2C Human Pre-designed siRNA Set A
    MEF2C Human Pre-designed siRNA Set A
  • HY-120877A
    (R)-MRT199665

    		MARK Salt-inducible Kinase (SIK) AMPK Apoptosis Cancer
    (R)-MRT199665 is an isomer of MRT199665 (HY-120877). MRT199665 is a potent and ATP-competitive, selective MARK/SIK/AMPK inhibitor with IC50s of 2/2/3/2 nM, 10/10 nM, and 110/12/43 nM for MARK1/MARK2/MARK3/MARK14, AMPKα1/AMPKα2, and SIK1/SIK2/SIK3, respectively. MRT199665 causes apoptosis in MEF2C-activated human acute myeloid leukemias (AML) cells. MRT199665 inhibits the phosphorylation of SIK substrate CRTC3 at S370 .
    (R)-MRT199665
  • HY-124514
    UC-857993

    		SOS1 Ras ERK Cancer
    UC-857993 is a selective SOS1-Ras inhibitor (Kd=14.7 μM, His6-SOS1cat), suppressing catalytic activity. UC-857993 also inhibits ERK and Ras activation, suppresses the growth of mouse embryonic fibroblasts (MEFs) .
    UC-857993
  • HY-135275
    BCL-XL-IN-4

    		Bcl-2 Family Cancer
    BCL-XL-IN-4 (compound 10) is a potent and selective BCL-XL inhibitor with Ki values of 0.042, 170 nM for BCL-XL, BCL-2, respectively. BCL-XL-IN-4 shows cytotoxicity .
    BCL-XL-IN-4
  • HY-175210
    STING-IN-16

    		STING Interleukin Related IFNAR Reactive Oxygen Species (ROS) Apoptosis Inflammation/Immunology
    STING-IN-16 is a STING inhibitor with IC50 values of 44 nM (human) and 32 nM (mice) for cellular STING inhibition. STING-IN-16 effectively inhibits the activation of the STING axis in both human and murine cells. STING-IN-16 can restore renal mitochondrial function, suppress reactive oxygen species (ROS) production, and reduce cell apoptosis. STING-IN-16 shows robust anti-inflammatory efiicacy in vivo. STING-IN-16 can be used for the study of autoimmune and autoinflammatory diseases .
    STING-IN-16
  • HY-10475G
    AM580

    CD336; NSC608001; Ro 40-6055

    		 RAR/RXR Cancer
    AM580 (CD336) (GMP) is AM580= (HY-10475) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AM580 is a selective RARα agonist .
    AM580
  • HY-126214S
    JH-RE-06-d6

    		DNA/RNA Synthesis Cancer
    JH-RE-06-d6 is deuterium labele JH-RE-06. JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Ki=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy .
    JH-RE-06-d6
  • HY-131037
    MB-0223

    		Dynamin Cancer
    MB-0223 is a potent and selective dynamin-related GTPase Drp1 partial inhibitor (IC50=1.3 μM) over other dynamin family members, Opa 1 and dynamin-1 (IC50>100 μM) .
    MB-0223
  • HY-W010270A
    Aurothiomalate disodium

    		TRP Channel NF-κB NO Synthase TREM receptor Arginase Metabolic Disease Inflammation/Immunology
    Aurothiomalate (disodium) is a TRPA1 inhibitor. Aurothiomalate (disodium) inhibits NF-κB activation and iNOS expression. Aurothiomalate (disodium) promotes M2 transformation of macrophages and increases the expression of TREM-2 and arginase-1. Aurothiomalate (disodium) can be used in the study of liver fibrosis/cirrhosis and arthritis .
    Aurothiomalate disodium
  • HY-139062
    C6 Urea Ceramide

    C6 Ceramide (d18:1/6:0) Urea; Cer(d18:1/6:0) Urea; D-erythro-Urea-C6-Ceramide

    		 Apoptosis Ceramidase Autophagy β-catenin Cancer
    C6 Urea Ceramide (Cer(d18:1/6:0) Urea) is an inhibitor of neutral ceramidase. C6 Urea Ceramide increases total ceramide levels in wild-type mouse embryonic fibroblasts (MEFs) and HT-29 colon cancer cells. C6 Urea Ceramide (5-10 μM) inhibits proliferation of HT-29 cells and induces apoptosis and autophagy, but is not toxic to non-cancerous cells. C6 Urea Ceramide decreases total and phosphorylated β-catenin levels in HT-29 and HCT116 cells, and induces colocalization of β-catenin with the 20S proteasome. C6 Urea Ceramide (1.25, 2.5, and 5 mg/kg) reduced tumor growth and increased C16, C18, C20, and C24 ceramide levels in tumor tissues in the HT-29 mouse xenograft model.
    C6 Urea Ceramide
  • HY-P5891
    TAT-SAMβA

    		PKC Cardiovascular Disease
    TAT-SAMβA is the peptide consist of RNAENFDRF (SAMβA; HY-P3429) conjugated to the cell penetrating TAT protein-derived peptide TAT47–57. TAT-SAMβA is a selective antagonist of Mfn1-βIIPKC association. TAT-SAMβA protects mouse embryonic fibroblast cells (MEFs) against oxidative stress-induced cytotoxicity .
    TAT-SAMβA
  • HY-174583
    Human MEF2C mRNA

    		mRNA Cancer
    Human MEF2C mRNA encodes the human myocyte enhancer factor 2C (MEF2C) protein, a member of the MADS box transcription enhancer factor 2 (MEF2) family. MEF2C has both trans-activating and DNA binding activities and may play a role in maintaining the differentiated state of muscle cells.
    Human MEF2C mRNA
  • HY-160840
    SPB-AAD

    		Fluorescent Dye Others
    SPB-AAD is a BFPX probe. SPB-AAD has covalent capture of in vitro assembled MEF2/DNA and NFAT1/DNA complexes .
    SPB-AAD
  • HY-RS26209
    Mef2a Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Mef2a Rat Pre-designed siRNA Set A contains three designed siRNAs for Mef2a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mef2a Rat Pre-designed siRNA Set A
    Mef2a Rat Pre-designed siRNA Set A
  • HY-RS23758
    Mef2d Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Mef2d Rat Pre-designed siRNA Set A contains three designed siRNAs for Mef2d gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mef2d Rat Pre-designed siRNA Set A
    Mef2d Rat Pre-designed siRNA Set A
  • HY-RS08310
    MEF2B Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MEF2B Human Pre-designed siRNA Set A contains three designed siRNAs for MEF2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MEF2B Human Pre-designed siRNA Set A
    MEF2B Human Pre-designed siRNA Set A
  • HY-170237
    SIK2/3-IN-1

    		Salt-inducible Kinase (SIK) Cancer
    SIK2/3-IN-1 (Compound 7S) is a selectively inhibitory agent of SIK2/3 with oral activity. SIK2/3-IN-1 can significantly inhibit tumor growth (without any body weight loss) in the MV4-11 AML mice CDX model. SIK2/3-IN-1 can be used in the research of MEF2C-dependent acute myeloid leukemia .
    SIK2/3-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: